Related Experiment Video
Updated: Sep 10, 2025

04:25
Author Spotlight: Bridging Gaps in Anatomy and Establishing a Foundation for Algorithmic Studies
Published on: December 15, 2023
2.8K
Segmentation of Brain Tumors Using a Multi-Modal Segment Anything Model (MSAM) with Missing Modality Adaptation.
Jiezhen Xing1, Jicong Zhang1,2
1School of Biological Science and Medical Engineering, Beihang University, Beijing 100191, China.
Bioengineering (Basel, Switzerland)
|August 28, 2025
Summary
This study introduces a novel multi-modal segment anything model (MSAM) for glioma tumor segmentation. MSAM demonstrates superior performance over U-Net, even with incomplete imaging data, showing its clinical potential.
Area of Science:
- Medical Imaging
- Artificial Intelligence
- Neuro-oncology
Background:
- Accurate glioma segmentation is crucial for treatment planning.
- Existing models struggle with multimodal data integration and missing data scenarios.
- Developing robust segmentation models for diverse clinical data is essential.
Purpose of the Study:
- To introduce a novel multi-modal segment anything model (MSAM) for glioma segmentation.
- To enhance brain tumor segmentation accuracy using multimodal MRI and diffusion tensor imaging data.
- To address the challenge of missing data in clinical settings.
Main Methods:
- Developed a multi-modal feature fusion block for integrating diverse imaging data.
- Implemented a missing modality training method to handle incomplete datasets.
- Compared MSAM against U-Net using Dice Similarity Coefficient and 95% Hausdorff Distance metrics.
Main Results:
- MSAM consistently outperformed U-Net across various modality combinations.
- Performance gains were notable when using structural MRI data alone.
- MSAM demonstrated robustness and adaptability to missing data, including smaller tumor regions.
Conclusions:
- MSAM offers a significant advancement in glioma segmentation, outperforming traditional methods.
- The model's ability to handle missing data makes it suitable for real-world clinical applications.
- Further research should explore MSAM's performance on varying tumor sizes and complexities.

